Purpose: MicroRNA-454 has been proven dysregulated in some human malignancies and correlated with tumor progression. However, its expression and function in non-small cell lung cancer (NSCLC) is still unclear. Thus, the aim of this study was to explore the effects of miR-454 in NSCLC tumorigenesis and development.
Methods: Using quantitative RT-PCR, we detected miR-454 expression in NSCLC cell lines and primary tumor tissues. The association of miR-454 expression with clinicopathological factors and prognosis was also analyzed. Then, the effects of miR-454 on the biological behavior of NSCLC cells were investigated. At last, the potential regulatory function of miR-454 on PTEN expression was confirmed.
Results: miR-454 was found to be up-regulated in NSCLC tissues and cell lines. High miR-454 expression was closely correlated with lymph node metastasis, advanced TNM stage, and shorter overall survival. Multivariate regression analysis corroborated that miR-454 overexpression was an independent unfavourable prognostic factor for patients with NSCLC. Down-regulation of miR-454 could significantly reduce NSCLC cell proliferation, enhance cell apoptosis, and impair cell invasion and migration in vitro, while up-regulation of miR-454 showed opposite effects. Further, PTEN was confirmed as a direct target of miR-454 by using Luciferase Reporter Assay.
Conclusions: These findings indicate that miR-454 may act as an oncogene in NSCLC and would serve as a potential therapy target for this disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biopha.2016.03.029 | DOI Listing |
In Vivo
December 2024
Laboratorio de Biología Molecular, Laboratorio Estatal de Salud Pública del Estado de México, Toluca de Lerdo, Mexico
Background/aim: Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, manifests a wide range of clinical symptoms ranging from mild to moderate and severe. Host-related factors influence the course of SARS-CoV-2 infection; for instance, the expression of host microRNAs (miRNAs) could influence the progression and complications of COVID-19. This study aimed to determine the expression pattern of endogenous miRNAs in 80 severe COVID-19 patients compared to a group of healthy individuals.
View Article and Find Full Text PDFRep Biochem Mol Biol
April 2024
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Reprod Biol
November 2024
Department of Reproductive Medicine, Guangzhou Women and Children's Medical center Liuzhou Hospital, Liuzhou, Guangxi 545616, China; Department of Reproductive Medicine, Liuzhou maternity and Child Healthcare Hospital, Liuzhou, Guangxi 545001, China; Guangxi Clinical Research Center for Obstetrics and Gynecology, China; Liuzhou Key Laboratory of Gynecologic Tumor, China. Electronic address:
Mol Cells
December 2024
Department of Pharmacology, College of Medicine, Institute of Natural Medicine, Hallym University, Chuncheon, Gangwon State, Republic of Korea. Electronic address:
miR-454-3p has been reported to be a tumor-suppressive microRNA (miRNA) in multiple cancer types. We identified the kinase STK33 mRNA, which is a high-risk factor for survival in neuroblastoma (NB) patients, as being a substrate of miR-454-3p in NB. Even though STK33 is an attractive target for several cancers, the development of inhibitors of STK33 has been challenging.
View Article and Find Full Text PDFCancer Rep (Hoboken)
October 2024
Guangxi Key Laboratory of Traditional Chinese Medicine Quality Standards, Research Center of Traditional Chinese Medicine and Ethnic Medicine, Guangxi Institute of Chinese Medicine and Pharmaceutical Science, Nanning, China.
Objectives: Glioblastoma multiforme (GBM) is considered the most assailant subtype of gliomas, presenting a formidable obstacle because of its inherent resistance to temozolomide (TMZ). This study aimed to characterize the function of lncRNA NEAT1 in facilitating the advancement of gliomas.
Methods: The expression level of NEAT1 in glioma tissues and cells was detected by qRT-PCR.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!